S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Price Target & Analyst Ratings

$0.46
+0.04 (+9.64%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.46
$0.46
50-Day Range
$0.41
$1.68
52-Week Range
$1.22
$8.45
Volume
564 shs
Average Volume
29,344 shs
Market Capitalization
$14.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Nabriva Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Strong Sell
Based on 1 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
9/28/22 to 9/28/23
1 Month Ago
8/29/22 to 8/29/23
3 Months Ago
6/30/22 to 6/30/23
1 Year Ago
9/28/21 to 9/28/22
Consensus Rating
Strong Sell
Strong Sell
Strong Sell
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/A$50.00
Predicted UpsideN/AN/AN/A305.10% Upside
Get Nabriva Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.


NBRV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NBRV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nabriva Therapeutics Stock vs. The Competition

TypeNabriva TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
1.00
2.66
2.49
Consensus RatingStrong SellModerate BuyHold
Predicted Upside1,247.66% Upside699.05% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/6/2023Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Underperform
(Data available from 9/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NBRV Price Target - Frequently Asked Questions

What is Nabriva Therapeutics's consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Nabriva Therapeutics stock is Sell based on the current 1 sell rating for NBRVthe . Learn more on NBRV's analyst rating history.

Do Wall Street analysts like Nabriva Therapeutics more than its competitors?

Analysts like Nabriva Therapeutics less than other Medical companies. The consensus rating for Nabriva Therapeutics is Strong Sell while the average consensus rating for medical companies is Moderate Buy. Learn more on how NBRV compares to other companies.


Stock Ratings Reports and Tools

This page (NASDAQ:NBRV) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -